Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.
Ebrahimi B, Viswanadhapalli S, Pratap UP, Rahul G, Yang X, Pitta Venkata P, Drel V, Santhamma B, Konda S, Li X, Sanchez ALR, Yan H, Sareddy GR, Xu Z, Singh BB, Valente PT, Chen Y, Lai Z, Rao M, Kost ER, Curiel T, Tekmal RR, Nair HB, Vadlamudi RK. Ebrahimi B, et al. Among authors: curiel t. NPJ Precis Oncol. 2024 May 24;8(1):118. doi: 10.1038/s41698-024-00612-y. NPJ Precis Oncol. 2024. PMID: 38789520 Free PMC article.
Crucial roles of the BRCA1-BARD1 E3 ubiquitin ligase activity in homology-directed DNA repair.
Wang M, Li W, Tomimatsu N, Yu CH, Ji JH, Alejo S, Witus SR, Alimbetov D, Fitzgerald O, Wu B, Wang Q, Huang Y, Gan Y, Dong F, Kwon Y, Sareddy GR, Curiel TJ, Habib AA, Hromas R, Dos Santos Passos C, Yao T, Ivanov DN, Brzovic PS, Burma S, Klevit RE, Zhao W. Wang M, et al. Among authors: curiel tj. Mol Cell. 2023 Oct 19;83(20):3679-3691.e8. doi: 10.1016/j.molcel.2023.09.015. Epub 2023 Oct 4. Mol Cell. 2023. PMID: 37797621 Free PMC article.
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors.
Murray CE, Kornepati AVR, Ontiveros C, Liao Y, de la Peña Avalos B, Rogers CM, Liu Z, Deng Y, Bai H, Kari S, Padron AS, Boyd JT, Reyes R, Clark CA, Svatek RS, Li R, Hu Y, Wang M, Conejo-Garcia JR, Byers LA, Ramkumar K, Sood AK, Lee JM, Burd CE, Vadlamudi RK, Gupta HB, Zhao W, Dray E, Sung P, Curiel TJ. Murray CE, et al. Among authors: curiel tj. Mol Cancer. 2024 Oct 30;23(1):242. doi: 10.1186/s12943-024-02147-z. Mol Cancer. 2024. PMID: 39478560 Free PMC article.
Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application.
Casas-Arozamena C, Vilar A, Cueva J, Arias E, Sampayo V, Diaz E, Oltra SS, Moiola CP, Cabrera S, Cortegoso A, Curiel T, Abalo A, Pamies Serrano M, Domingo S, Padilla-Iserte P, Arnaez de la Cruz M, Hernández A, García-Pineda V, Ruiz-Bañobre J, López R, Matias-Guiu X, Colás E, Gil-Moreno A, Abal M, Moreno-Bueno G, Muinelo-Romay L. Casas-Arozamena C, et al. Among authors: curiel t. J Exp Clin Cancer Res. 2024 Sep 20;43(1):264. doi: 10.1186/s13046-024-03158-w. J Exp Clin Cancer Res. 2024. PMID: 39304963 Free PMC article.
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.
Chand D, Savitsky DA, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P, Soh KT, Wu W, Wilkens MK, Udartseva O, Vincent S, Joshi B, Keith JG, Manrique M, Marques M, Tanne A, Levey DL, Han H, Ng S, Ridpath J, Huber O, Morin B, Galand C, Bourdelais S, Gombos RB, Ward R, Qin Y, Waight JD, Costa MR, Sebastian-Yague A, Rudqvist NP, Pupecka-Swider M, Venkatraman V, Slee A, Patel JM, Grossman JE, Wilson NS, Von Hoff DD, Stebbing J, Curiel TJ, Buell JS, O'Day SJ, Stein RB. Chand D, et al. Among authors: curiel tj. Cancer Discov. 2024 Dec 2;14(12):2407-2429. doi: 10.1158/2159-8290.CD-24-0190. Cancer Discov. 2024. PMID: 39083809 Free PMC article.
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.
Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, Wilky BA, Pimentel A, Mahadevan D, Balmanoukian AS, Sanborn RE, Schwartz GK, Abou-Alfa GK, Segal NH, Bockorny B, Moser JC, Sharma S, Patel JM, Wu W, Chand D, Rosenthal K, Mednick G, Delepine C, Curiel TJ, Stebbing J, Lenz HJ, O'Day SJ, El-Khoueiry AB. Bullock AJ, et al. Among authors: curiel tj. Nat Med. 2024 Sep;30(9):2558-2567. doi: 10.1038/s41591-024-03083-7. Epub 2024 Jun 13. Nat Med. 2024. PMID: 38871975 Free PMC article. Clinical Trial.
Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers.
Biswas S, Mandal G, Anadon CM, Chaurio RA, Lopez-Bailon LU, Nagy MZ, Mine JA, Hänggi K, Sprenger KB, Innamarato P, Harro CM, Powers JJ, Johnson J, Fang B, Eysha M, Nan X, Li R, Perez BA, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. Biswas S, et al. Among authors: curiel tj. Immunity. 2023 Nov 14;56(11):2570-2583.e6. doi: 10.1016/j.immuni.2023.09.013. Epub 2023 Oct 30. Immunity. 2023. PMID: 37909039 Free PMC article.
184 results